Evidence map›Paper›PMID 39272117›Full record

ArticleResearch involvement and engagement2024

Patient engagement as a collaborative process in a large Dutch COVID-19 vaccination study (RECOVAC) - insight into the contribution of patient engagement and learnings for the future.

J P M Vervoort, W S Konijn, D E M C Jansen, C Boersma, J de Zeeuw, M M Ho-Dac-Pannekeet, R T Gansevoort, A L Messchendorp, J S F Sanders, R de Wildt-Liesveld

3 registry-linked trialsAbstract read
In one paragraph

Article in Research involvement and engagement, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04741386 completednot on this map

The Immune-response and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant - A Prospective, Controlled, Multicenter Cohort Study by the RECOVAC Consortium

Typeobservational_patient_registrySponsorUniversity Medical Center GroningenRan2021 to 2022Enrolled854ConditionsCovid19, Chronic Kidney DiseasesArmsSARS-CoV-2 vaccination
NCT04841785 completednot on this map

The RECOVAC LESS CoV-2 Study - Long Term Efficacy and Safety of SARS-CoV-2 Vaccination in Patients in Patients With Chronic Kidney Disease Stage G4-G5, on Dialysis or After Kidney Transplantation

TypeobservationalSponsorUniversity Medical Center GroningenRan2021 to 2023Enrolled4,868ConditionsCovid19, SARS-CoV Infection, Chronic Kidney DiseasesArmsmailer-based finger-prick
NCT05030974 phase4completednot on this map

Optimal Repeated Dose Strategy for SARS-CoV-2 Vaccination in Kidney Transplant Patients A Prospective, Randomized Multicenter Study by the REnal Patients COVID-19 VACcination (RECOVAC) Consortium

TypeinterventionalSponsorUniversity Medical Center GroningenRan2021 to 2022Enrolled336ConditionsCovid19, Kidney Diseases, Vaccine Response Impaired, SARS-CoV2 InfectionArmsmRNA-1273, Ad26.COV2.S vaccine
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

J P M Vervoort *Dutch Kidney Patients Association (NVN), Bussum, The Netherlands. j.p.m.vervoort@rug.nl.
W S Konijn *Dutch Kidney Patients Association (NVN), Bussum, The Netherlands.
D E M C JansenDepartment of Primary Care and Long Term Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
C BoersmaDepartment of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J de ZeeuwDepartment of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
M M Ho-Dac-PannekeetDutch Kidney Patients Association (NVN), Bussum, The Netherlands.
R T GansevoortDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
A L MesschendorpDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J S F SandersDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
R de Wildt-LiesveldDutch Kidney Patients Association (NVN), Bussum, The Netherlands.

Funding

Nierstichting 21OP + 036ZonMw 10430072010002
6 · The paper itself

Abstract

backgroundThe need for patient engagement in health research has been increasingly acknowledged and accepted in recent years. However, implementation is still limited due to lack of evidence on its value and lack of guidance on how to implement patient engagement. This study aims to provide insight into the contribution of patient engagement in the RECOVAC project, which studied COVID-19 vaccination in kidney patients, and formulate concrete practice-based action perspectives for patient engagement.

methodsWe used a qualitative participatory mixed methods approach, based on the Patient Engagement Monitoring and Evaluation (PEME) framework. Patient engagement and data collection were based on the Reflexive Monitoring in Action (RMA) approach. Data collection included participant observations, open ended questionnaires and interactive reflection sessions. Qualitative analysis was done via a thematic approach.

resultsWe have described the process of patient engagement systematically, provided insight in its value and found that there is a need for clear aims, expectations and preparations from the start of the engagement process. We have shown that reflection throughout the process is of utmost importance and the same applies to clear communication between researchers and patient representatives. By being part of the consortium patient representatives had direct access to information, straight from the source, on for example the vaccination schedule and medication availability and had indirect influence on decisions made by the National Institute for Public Health and the Environment (RIVM) on preventive measures and treatment against COVID-19. Having experienced patient representatives is important, otherwise training needs to be provided. We also found that patient engagement had impact on conduct and outcomes of research activities itself and may have impact on future research and patient engagement activities in general.

conclusionPatient engagement has changed the course of the project. Concrete practice-based action perspectives have been formulated, which are already being implemented by the Dutch Kidney Patients Association (NVN). Studying patient engagement in a high pace project with high public interest has resulted in lessons learned and will help prepare and implement patient involvement in future research projects. CLINICAL

trial registrationThe RECOVAC studies in which the patient engagement took place are registered at clinicialtrial.gov (NCT04741386 registration date 2021-02-04, NCT04841785 registration date 2021-03-22 and NCT05030974 registration date 2021-08-20).

Indexed as

Collaborative processCOVID-19 vaccinationKidney patientsPatient engagementPatient engagement monitoring and evaluation (PEME) framework

Identifiers

PMID39272117
PMCPMC11395945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.